

ACT EU Multi-stakeholder Meeting on Decentralised Clinical Trials

4 October 2022





Etiquette for ACT EU multi-stakeholder meeting on decentralised clinical trials



Please note that this meeting is being recorded. The recording, or parts thereof, may be used/published on the EMA website after the event for training and communication purposes. By registering for this event, you have consented to this recording and the processing of your personal data by EMA in accordance with <u>Regulation (EU)</u> <u>2018/1725</u>.

For information on the processing of personal data, please refer to the <u>General EMA Privacy</u> <u>Statement</u> and the <u>EMA Privacy Statements on the</u> <u>organisation of meetings and events</u>.



Welcome & opening remarks

Chairs: Emer Cooke, EMA / Peter Arlett, EMA / Greet Musch, FAMHP/CTCG



Agenda – ACT EU Multi-stakeholder Meeting on Decentralised Clinical Trials 4 October 2022 09:00 - 17:00 (CEST)

Onsite at European Medicines Agency & live broadcast and recording (for plenary sessions)



4 ACT EU Multi-stakeholder Meeting on Decentralised Clinical Trials



4 October 2022 (09:30 - 13:00)

Room 1C/live broadcast and recording

- 09:30 Welcome and introduction
- 09:50 Authority Perspective
- 10:30 Sponsor and CRO Perspective

20' coffee break

- 11:40 Patient and Investigator Perspective
- 12:50 Closing session

11:20

• 13:00 End plenary session



Scope of the DCT collaboration across the European Medicines regulatory network



Decentralised Clinical Trials (DCT)

The DCT approach seeks to take advantage of the technological and scientific progress to introduce new methodologies to the conduct of clinical trials with the aim to make clinical trials <u>more easily</u> <u>accessible and participation more convenient for trial participants</u>.

The DCT methodology is based on elements such as:

- Home health visits including teleconsultation and visits where health care professionals come to the trial participant's home,
- **Direct shipment** of investigational medicinal products (IMPs) to trial participants,
- Electronic informed consent procedures.



Major impact on the environment for conduct of clinical trials





Recommendations on decentralised elements in CTs from European Medicines Regulatory Network

DCT Recommendation paper


Harmonised perspective focused on

- Trial participant-centred and risk-based approach
- Investigator and sponsor oversight
- Reliable and robust data fit for purpose

National provisions overview

Member state specific provisions

 Where national legislation does not currently allow for alignment



First publication: end Q4 2022

Best practice for EU CT authorisation and inspection Update as knowledge and experience evolve

Cross disciplinary recommendations

45 experts across 12 MSs – 25 onsite today

<u>Driven by</u>



Incorporating perspectives by



Scope of todays meeting

Challenges → manage and mitigate Opportunities

To create a harmonised approach and facilitate use of DCT elements in EU clinical trials, maintaining:

- Trial participant safety, right and dignity
- Reliable and robust data fit for purpose



Authority Perspective





DCT recommendations from the European Medicines regulatory network

Presented by Solange Levision (CCMO) & Monique AL (CCMO)



Some points of attention



Recommendation paper:

- focus is on decentralised elements in the conduct of clinical trials
- GDPR specific requirements not provided
- principles and rules "traditional clinical trials" similar for clinical trials with decentralised elements will not be repeated unless it fits a purpose
- definition on decentralised clinical trial, decentralised elements, etc not included to avoid getting caught in words
- the recommendation paper will evolve over time

Recommendation paper on decentralised elements in clinical trials in the EU

Table of content:

- 1. Introduction, scope and general considerations
- 2. Clinical trial oversight: roles and responsibilities
- 3. Informed consent process
- 4. Delivery of medicinal products and administration at home
- 5. Trial related procedures at home
- 6. Defining and handling source data
- 7. Trial monitoring

./	
V	
\checkmark	
V	
1	


Basic principle that **right**, **safety and well being** of trial participants to be **protected** and **prevail** over all other interests

Adherence to EU and national applicable laws, regulations and established standards for clinical trials (overview of national provisions in appendix of recommendation paper)

Involvement of **patients and investigators** in an early and sustained manner – implementation of DCT elements according to patient and investigator needs.

Trial specific **rationale** for selected decentralised elements, where any transfer of **burden to trial participants or investigators** should be weighed against the benefits of using decentralised elements in the clinical trial.

Trial specific **risk-benefit assessment**, focused **on selected decentralised elements** which may have an impact on scientific validity, patient safety, benefit/risk ratio or protection of participants rights.



Appropriate training and guidance of third parties, trial participants and investigators.

Qualifications of third parties performing trial related tasks.

Generating **reliable and robust data** fit for use for regulatory decision making and/or publication in peerreviewed journals.

IT devices/technologies developed and utilized should be **fit for purpose**. Use of computerised systems or creation/capture of electronic data should be compliant with GCP-IWG Guideline on computerized systems and electronic data in clinical trials (EMA/226170/2021 – to be published).

A **contingency plan** should be in place to minimise the impact of any risk (e.g. malfunction of a digital tool, lack of web connection...)



Classified as public by the European Medicines Ager

Clinical trial oversight: roles and responsibilities

- \downarrow On site visits
- \uparrow Involvement of third parties
- \uparrow Use of e-systems
- ↑ Amount of incoming data (wearables, home nursing staff, patient reported outcomes, etc.)



More tasks are delegated - responsibilities stay the same (GCP)

It should be ensured that the sponsor and investigator keep oversight on the safety and well-being of the trial participants:

- → Document which tasks are conducted at what place, when, and by whom (contractual agreements, protocol)
- \rightarrow Clear communication plan between the different parties involved
- → Procedures should be in place to handle the constant flow of information (safety alerts) so that the investigator has appropriate oversight of patient treatment, safety and well being.

Informed consent process



Hybrid forms possible:


- Informed consent interview \rightarrow remote or on site
- Patient information (leaflet) \rightarrow digital, on paper, or video
- Signature \rightarrow electronic or 'wet ink'



Risk-based approach:

- \rightarrow Interview: Consider importance of <u>face-to-face</u> (use of videocall).
- Patient information leaflet: Awareness of participants who cannot or prefer not to use electronic technology (non-digital methods available).
- → Signature: Depending on national legislation. Requirements described in *Guideline on* computerised systems and electronic data in clinical trials.

Delivery of medicinal products and administration at home



Basic principles:

- \rightarrow Highly restricted access to trial participants contact details.
- → The investigator remains responsible for requesting and initiating each shipment of IMP.
- → Investigator and sponsor should assess whether it is feasible with regard to storage conditions of IMP.
- \rightarrow Consider who can do the administration of the IMP at home.
- \rightarrow Participants should be clearly instructed on the use and storage of the IMP.

- From the sponsor depots/manufacturer/distributor to the participant's home
- From the pharmacy of the investigator's site
- From a local pharmacy (close to the participant's home)



specific requirements for the IMP shipment are given

Clinical Trial Procedures at Home

Focus only on trial related procedures performed at the trial participant home by site personnel, third party or trial participant



- → Feasibility of performing trial related procedures at home
- → Impact on trial participant/investigator relationship with less on-site visits on compliance of trial participant (new role of GP?)
- → Need for on-site visits or visits at home (by investigator or other qualified persons)
- → Provision of devices by sponsor to capture data (as alternative for private devices)

Defining and handling of source data

Focus is on raising awareness:

↑ percentage of data collected outside clinical trial site↑ complexity of data flow

 \rightarrow Same principles regardless of the location of data capture

→ Sponsor responsibility to ensure that investigator has control and continuous access to source data, irrespective of location of data capture



- → Reference to the EMA GCP Q&A B.3 "How and where should source data be defined?" and GCP Q&A B.5 "What are the expectations of the investigator's copy of the CRF when using a web-based application?"
- → Reference to SAWP opinion and notice to sponsor on validation and qualification of computerised systems

Remote monitoring



Recommendations on a high level as appropriate and in line with national provision.



Thank you for your attention!





Authority Perspective

Q & A





Sponsor and CRO Perspective





Industry sponsor perspective: Opportunities and challenges for the use of DCT elements in clinical trials





Industry sponsor perspective: Opportunities and challenges for the use of DCT elements in clinical trials











Alison Bond Director, Global Regulatory and R&D Policy, Amgen Co-chair, EFPIA DCT Team





Bringing the trial to the participant – Providing options, reducing burden & facilitating participation

Traditional Clinical Trial Model



- Wherever the participant is, they generally have to travel to the site
- For many participants this can involve great distance to get to a specialist centre
- The trial is organised around the site

Decentralised Clinical Trial Model



- Some or all of the assessments can be undertaken local to the participant or remotely
- The trial is organised around the participant
 & considers the needs of the site



efpta

The selection of DCT elements depends on the trial design & participant population



Telemedicine



Direct to Participant IMP Shipment and Administration



Mobile Healthcare Providers (e.g. Home Nurses)



Electronic Informed Consent / Remote Consenting



Local Healthcare Providers (e.g. General Practitioner)



Concierge Services



Local Laboratories and Imaging Centres



Digital Health Technologies (e.g. wearables)



Opportunities for further enhancing research through DCT approaches

Remove geographical barriers to participation

Potential to increase diversity of trial participants

Reduce burden on participants and caregivers

Empower participants with choice

Facilitate innovative more meaningful data collection & novel endpoints using digital health technologies



Perceived and experienced challenges of DCTs

Operational & Technology

- Data consolidation
- Complexity of data flows
- Potential for selection bias
- Impact on existing operations

Relationships & oversight

- Participant/Investigator/sponsor relationship
- Investigator oversight of patients & distributed care team
- Reporting and handling of potential AEs/SAEs
- Site training & acceptance of the use of DCT elements

Data privacy/protection

- Participant names and addresses in platforms
- Electronic signatures

Data quality

- Comparability of data for site & remote assessments
- Data acceptability & management of large data sets

Regulatory framework

- Lack of regulatory guidance globally
- Fragmentation adaption required according to local laws and regulations

Preserve participant safety, rights and well-being and data integrity, to provide reliable trial results



What are we doing to support use of DCT elements?

DCT elements, if used, are selected to fit the participant population, Investigational Product, trial design & country

Working together across trade associations and industry initiatives to have a shared understanding

Collaboration, sharing expertise & experience, to employ best practice across sponsors

Engagement of patients, advocates and HCPs in trial design, including DCT elements

All parties have the same aim – Participant rights, safety and wellbeing and reliable trial results



ACT EU DCT WORKSHOP 4 OCTOBER 2022

What is needed to further advance use of DCT elements?

EU: Clearer understanding of differences between Member States - harmonised & transparent approach for use of DCT elements

Globally: ICH E6 (R3) support use of DCT elements & provide a degree of harmonisation (EU guidance should be aligned)

Agreement on where in a CTA DCT elements to be used in a trial should be described and justified

Recognition of acceptability of data from trials with DCT elements – recommendations around (statistical) approaches for data All parties have the same aim – Participant rights, safety and wellbeing and reliable trial results





The future of Decentralised Clinical Trials is.....



The future of Decentralised Clinical Trials is....




DCT elements become part of the clinical trial toolbox!



ACT EU DCT WORKSHOP 4 OCTOBER 2022







Classified as public by the European Medicines Agency



Academic Sponsor perspective: Experiences on use of DCT elements during covid-19





Academic Sponsor perspective: Experiences on use of DCT elements during covid-19

Vassilis Golfinopoulos, MD, PhD EORTC Headquarters Director ACT EU Multi-stakeholder Meeting on Decentralised Clinical Trials 4 October 2022

The future of cancer therapy

Classified as public by the European Medicines Agency

Any DCT measures were triggered by the sites and needed centralised oversight

- **Centralization** of COVID-19 related communications
- Early sponsor assessment of COVID-19 impact on ongoing trials, opening new trial sites, ongoing recruitment and starting new trials
- Clear communication to investigators and site staff on COVID-19 measures considerable based on:
 - Risk-benefit assessment
 - Local/national recommendations and measures



Remote informed consent on request

- Initial consent remained on site
- **Reconsent** in case of amendment or urgent changes in trial conduct:

via phone or video call followed by email confirmation



Imaging exams done at remote site

In relation to imaging procedures, order of preference*:

- Onsite
- Offsite, on time
- Onsite, delayed (e.g., due to travel restrictions)
- Offsite, delayed (e.g., due to travel restriction)
- Skip the imaging only if impossible to perform due to travel restrictions or safety consideration.

* Unless imaging **must**, per protocol, be done at the main site when imaging result drives treatment allocation.



Patients visits allowed to switch to remote

- Patient visits could be changed to phone visits
- Standard repeated assessments (e.g., biochemistry) could be done by contracted laboratories
- Optimal **traceability** of protocol deviations due to COVID-19
 - Sites requested to discuss deviations with sponsor before implementation
 - Documentation of deviation in case report forms and medical records



Study treatment delivered at patients' home on request

- All oral formulations
- Shipment by vendor and temperature controlled
- Use of a Pharmacy Guideline Addendum
- Acknowledgment by patient once received
 - Ensure that content of the delivery is correct and undamaged
- Where assessments (e.g. blood counts, biochemistry) are required prior to study treatment administration
 - At the centre or contracted laboratory
 - Centrally reviewed



Investigators should tell their patients that drug suppliers will get their name and address for delivery



Direct to patient delivery needs work for each case

For 52 patients, from 19 sites, in 10 clinical trials

Study team involvement

- The regulatory manager checks the national guidance to assess what is allowed and what are the responsibilities of each party.
- The project manager calculates the additional cost.
- The medical monitor approves each request. Please note that whether or not directto-patient shipments are possible in each study has already been discussed while drafting the COVID-19 letter.
- The clinical research associate is informed.

Note to the trial master file for all.



Example of one member state (1/3)

- COVID-19 measures that have a significant impact on the protection and safety of participants (e.g., delivery of treatments to the patient's home) were put in place as Urgent Safety Measures
 - Followed by submission of substantial amendment to regulatory bodies
- Transitional measures during the pandemic period were submitted as appendix to the protocol to regulatory bodies



Example of one member state (2/3)

- Impact of crisis on all hospitals independent of size (20 sites reporting)
- Pharmacies kept open allowing drug reception during crisis
- Requested shipment of IMP to patient's home in 7 studies
- Patient visits: remote visits and use of local laboratories



Example of one member state (3/3)

- On-site monitoring: put on hold, follow-up with the site by phone
- Remote visits: discussing actual protocol deviations, assess IMP in stock, support data entry, follow-up and closure of major observations from past monitoring visits
- No source data verification
- Treatment dispatched to patients abroad, if unable to travel to the country



In oncology, we are not ready for fully remote procedures

Capability for decentralised processes comes **on top** of existing ones and requires different setup per member state

One can imagine specific clinical scenarios with decentralised-only processes (for example, follow-up of cancer patients) – these trials would assess the remote processes as much as the main trial endpoints



Thank you

vassilis.golfinopoulos@eortc.org

The future of cancer therapy

Classified as public by the European Medicines Agency



CRO Insights and Experiences: How to solve identified challenges on the implementation of DCT elements in clinical research

Presented by Yoanni Th. Matsakis (EUCROF) & Fiona Maini (ACRO)







CRO Insights and Experiences: How to solve challenges on the implementation of DCT elements in clinical research

EU DCT Workshop 4 October, EMA, Amsterdam

Joint session between ACRO and EUCROF

Fiona MAINI Chair of the ACRO DCT Working Party Yoanni Th. MATSAKIS EUCROF Executive Board

EU DCT 04/10/2022 - CRO Perspective

Points for consideration

CYBERSECURITY - GDPR

Patient Safety

Data Protection

Quality of data

HYBRID STUDIES – DATA HETEROGENEÏTY



EU DCT 04/10/2022 - CRO Perspective

Classified as public by the European Medicines Agency

Topic 1

Regulatory harmonization

DCT elements that are implementable in some countries and regulatory jurisdictions but not in others:

- Electronic Informed Consent & Electronic Signature
- Telehealth visits
- Home Health (Nursing) Services
- Direct to Patient Shipment of the Investigational Medical Product ...

Can some hybrid DCT elements be deployed in some countries and not in others under the same protocol? And for those countries in which DCT elements are not deployable, can we deploy traditional/in-person approaches under the same protocol?

Will this point be addressed in the recommendations in preparation ? Is it possible to implement some harmonization process & how ?



Topic 2

Site readiness

DCT is having multiple impacts on how clinical research is carried out in Clinical Sites:

- Multiple sponsors with multiple technologies to be implemented ...
- Some technologies may be highly site dependent : EMR, telehealth visits systems ...
- Sites may not accept some of the suggested options ?
- They may require upgrades both from technical and organizational standpoint : e.g. for rSDV giving access to the EMR system of the hospital and only to the "need to know" patient records ...
- Interoperability between CR systems and HIS software ?
- How to handle DPIA in certain situations ?

We witness the development of "proof-of-concept" approaches with sponsor / sites / CROs partnerships...

What would be EMA's recommendations on such issues ? How shall sponsors (academic and private) handle such heterogeneous situations ? Is this point addressed ? Shall we envisage some specific action plan ?



Topic 3

Data Protection

The EU GDPR regulation is often perceived as an "inhibitor" for the adoption of innovation as it introduces new concepts for which there are different perceptions and obligations to sponsors and sites (DPIA, processes registries ...)

To our view, it is an **innovative regulation** that shall facilitate the adoption of technological and organizational innovations for DCTS :

- Articles 40 & 41 of the General Regulation foresee the implementation of codes of conducts in domains with specificity, as well as other mechanisms (certifications ...)
- The regulator provides to the stakeholders a unique opportunity to **co-build the regulation**
- A cooperation mechanism to create the conditions of a harmonized landscape throughout the 27 EU Member States
- Through the Process / Controller / Processor new concepts, contribute to better define responsibilities & mitigate cybersecurity risks and foster transparency and trust

Should Data Protection issues be left outside of the domain, and the opportunities offered by GDPR codes of conduct (or other approaches) could at least be mentioned and related initiatives supported...



Other topics for further discussions

Protocol flexibilization / Hybrid situations

Is there a way from the regulatory viewpoint to allow patients to change in-person versus remote visits during a DCT randomly and at their convenience? Or must patients commit to one way of participating in a DCT either remote or in person as dictated by the protocol?

Can differences in the adoption of DCT tools & methods among sites be allowed in a the same trial ? Etc ...

Responsibility / role of local HC providers versus DCT personnel

When is a local healthcare provider considered part of the DCT personnel? When is a local healthcare provider just that and not part of DCT personnel? How are responsibilities split between investigator and home nurses" ?

Shall we reassess the scope of responsibility of the hospital investigator: keep the supervision of the study to the investigator, but limit the responsibility for homecare to the homecare healthcare professionals



EUCROF relevant activities

https://www.eucrof.eu/news-eucrof/publications https://cro.eucrof.eu/eucrof-code-public-registry

- Electronic Informed Consent Implementation Guide March 21
- Propositions Paper on Remote SDV/SDR (endorsed by EFPIA 2 June 22)
- EUCROF GDPR Code of Conduct for Service Providers in the 27 EU Member states
 - Create the conditions of trust & confidence to foster innovation for better care with appropriate patient involvement
- Implementing Decentralised Clinical Trials in Italy (June 2022)
- Recommendations on DCTs by FR Working Group ...



Thank you for your attention!

Contributing Members' Contact Information

- Dehlinger Kremer, Martine president@eucrof.eu EUCROF President
- Herry, Florence <u>fherry@libheros.fr</u> EUCROF / France
- Lindroos , Mika <u>mika.lindroos@Signanthealth.com</u> EUCROF / Finland
- Maini, Fiona Fiona.MAINI@3ds.com ACRO / UK
- Matsakis, Yoanni Th. <u>yma@tentelemed.com</u> EUCROF Executive Board
- Orlova , Valeria<u>Valeria.ORLOVA@3ds.com</u> EUCROF / UK
- Rodriguez-Chavez , Isaac <u>Isaac.RodriguezChavez@iconplc.com</u> EUCROF / US
- Van Dijk, Antoinette <u>antoinette.vandijk@doresearch.ch</u> EUCROF / Switzerland
- Yeomans, Alan <u>Alan.Yeomans@viedoc.com</u> EUCROF / Sweden



ACRO DCT Working Party

Overview of the ACRO DCT Tool kit for for the

Accelerating Clinical Trials in the EU Workshop

4th October 2022 Fiona Maini ACRO DCT WP Chair





Introducing the ACRO DCT WP Tool Kit



Classified as public by the European Medicines Agency

Accelerating DCT in the EU

Key Learnings and Recommendation s



DCT processes and technologies are established. Case studies, lessons learned, best practice recommendations, and training tools are available to help inform the EU DCT Recommendations.

Recognising variability across Member States

There are variations in national legislation provisons, regulation, and guidance on key DCT processes and tools (e.g., electronic informed consent, direct-to-patient shipment, and remote source data verification and review).

Enabling transparency of Member State requirements

The development of a central repository of national legislation, regulation, and guidance -- on each DCT process and tool (e.g., eConsent, DTP shipment, rsDV etc.) -- would mitigate challenges for sponsors and CROs in trying to execute pan-European DCTs.



Enabling greater coordination across regulatory agencies

DCTs and digital technologies highlight the importance of data protection. Greater communication and coordination between (1) health regulators and (2) data protection regulators, other regulations such as eIDAS– at both the EU level and the Member State level – would help advance DCTs.

CELEBRATING 20 YEAR

Appendix: Further Details for reference

ACRO DCT WP Toolkit

ACRO DCT TOOLKIT



ACRO Member Companies

CLARIO.







Veeva

Part of Thermo Fisher Scientific

S MEDIDARA



medrio

ORACLE saama Syneos verily



65

CRO Insights and Experiences: Contributors to this joint session between ACRO and **EUCROF**

Speakers	 Yoanni Matsakis <u>yma@tentelmed.com</u> 	 Fiona Maini – <u>Fiona.maini@3ds.com</u>
Contributors	 Alan Yeomans <u>Alan.Yeomans@viedoc.co</u>m Antoinette Vandijk <u>antoinette.vandijk@doresearch.ch</u> Florence Herry- <u>fherry@libheros.fr</u> Isaac Rodriguez-Chavez <u>Isaac.RodriguezChavez@iconplc.com</u> 	 Karen Noonan - <u>knoonan@acrohealth.org</u> Martine Dehlinger Kremer <u>Martine.DehlingerKremer@iconplc.com</u> <u>president@eucrof.eu</u> – EUCROF President Mika Lindroos- <u>mika.lindroos@Signanthealth.com</u> Valeria Orlova - <u>Valeria.ORLOVA@3ds.com</u>







Sponsor and CRO Perspective

Q & A







Coffee Break - 11.20 - 11.40h

Next up: Patient and Investigator Perspective



Broadcasted and Recorded Meeting



Chat is disabled mi



Please mute your microphone after speaking Please note that this meeting is being recorded. The recording, or parts thereof, may be used/published on the EMA website after the event for training and communication purposes. By registering for this event, you have consented to this recording and the processing of your personal data by EMA in accordance with <u>Regulation</u> (EU) 2018/1725.

For information on the processing of personal data, please refer to the <u>General EMA Privacy Statement</u> and the <u>EMA</u> <u>Privacy Statements on the organisation of meetings and</u> events.



Patient and Investigator Perspective





Patient Perspective

Presented by Julián Isla (COMP and Dravet Europe)




Decentralized clinical trials

A patient view

Julian Isla Dravet Syndrome European Federation













Microsoft Consulting Services. Al

Founder

European Syndrome Federation founder

TAG. Therapeutic Advisory Group member

Orphan Drug Committee member

Scientific Advisory Board

I attend this conference as an individual expert, and do not represent the EMA. The views expressed here are my personal views, and may not be understood or quoted as being made on behalf of the EMA or reflecting the position of the COMP


CV

http://www.ema.europa.eu/docs/ en GB/document library/contacts /islaj_CV.pdf

DOI

http://www.ema.europa.eu/docs/ en GB/document library/contacts /islaj DI.pdf

Maybe the name is not correct



And this is happening right now

	JROPEAN MEDIC ence medicines health					Search
Medicines 🗸	Human regulatory 🗸	Veterinary regulatory $ {m arsigma} $	Committees 🗸	News & events 🐱	Partners & networks 🗸	About us 🗸
	ic disorder	tion of medi s 	cinal pro	oducts in	the treatm	ent of
Current ef Document	ffective version t history - Revision 3 t history - Revision 2					
This document disorders.	provides guidance on t	he development of <u>medic</u>	inal products for t	he treatment of epi	leptic	

Clinical recurrent seizures are the **primary** marker of the condition. They are of several types as classified in the International Classification of Epileptic Seizures, mainly: generalised onset, focal onset, which may become secondarily generalised and unclassified seizures.¹

Clinical investigation of medicinal products in the treatment of epileptic disorders | European Medicines Agency (europa.eu)

Classified as public by the European Medicines Agency

How many seizures?

Hybrid could be an option

Fully decentralized +





→ Hybrid

All trial procedures are conducted virtually, enabled by digital technologies and supply delivery Less complex trial procedures that don't require in-person visits (eg, vital signs, electrocardiograms) are conducted via telehealthcare, remote data collection, or direct-to-patient supply Less complex trial procedures that require in-person visits (eg, injections) are conducted via mobile clinicians or alternative sites (eg, mobile clinics, retail sites)

ĀY

Complex trial procedures (eg, complex screening protocols, cell therapy, magnetic resonance imaging) are conducted via research sites (eg, academic medical centers) or local hospitals

All trial procedures are conducted at a research site (eg, academic medical center)

Fully centralized

Patients should make a choice

Decentralization can lower motivation if it is forced

It could be an issue for people with low technical skills


Physicians' technical skills as a barrier

<u>Med Educ Online.</u> 2022; 27(1): 2114851. Published online 2022 Aug 28. doi: <u>10.1080/10872981.2022.2114851</u> PMCID: PMC9423824 PMID: <u>36036219</u>

Digital health understanding and preparedness of medical students: a crosssectional study

Martin Baumgartner, Christoph Sauer, Kathrin Blagec, and Georg Dorffner

► Author information ► Copyright and License information <u>Disclaimer</u>



Classified as public by the European Medicines Agency

"Distance" could be an problem

But we can mitigate it with:

- Hot line
- Nurses and physicians availability
- Visits to patient home if he wants
- Telemetry
- Digital assistants



Design the clinical trial with the patient

- Apps for capturing data need UX experts and co-design with patients
- Design depends of the severity of the condition
- Severity drives motivation
- Don't forget the human touch



What about data privacy?

- Decentralization means patient data transfer and custody on digital assets
- This is underestimated for most of projects
- But it's easy to solve with a PIA (Privacy Impact Assessment) done by a data security company





Patient is the owner of the data Data should go back to patient after CT is done

- My son participated in two clinical trials
- Any data was shared with me
- Any data was reused
- My work has been lost

BOV.UK	> <u>Technology in health and social care</u> > <u>Data saves liv</u>	es: reshaping health and social care with data
Department		
of Health & Social Care		
Policy paper	s lives respaning	health and
Data save	es lives: reshaping	health and
Data save social car	es lives: reshaping e with data	health and
Data save		health and
Data save social car		health and

julian.isla@dravet.eu

Thanks



Classified as public by the European Medicines Agency



Investigator Perspective

Presented by Dr. Filippo Pieralli (University Hospital Careggi)



Investigator perspective


Filippo Pieralli

University Hospital Careggi – Firenze – Italy

Department of Clinical Research - FADOI

Classified as public by the European Medicines Agency

Patients' opinion about DCTs



SURVEY 1: CISCRP 2019 PERCEPTIONS AND INSIGHTS STUDY; SURVEY 2: CISCRP SURVEY : PATIENT INSIGHTS ON FACTORS IMPACTING CLINICAL TRIAL PARTICIPATION DURING THE COVID-19 PANDEMIC (AUG20)) Survey 3: BTKi survey May2020; Survey 4 : SCRS WHITE PAPER (site survey): Impact Assessment of Decentralized Clinical Trials (May/20)

Classified as public by the European Medicines Agency

Clinicians opinion on DCIS



70%

Of clinicians wants the activation of more rapid procedures



79%


Of clinicians refers that patients waste more than 25% of their in activities not directly related to the trial or study.



69%

Of clinicians with expertise on DCTs reports very good retention of patients in the study, even more than traditional clinical trials, and high compliance to procedures.

Decentralized Clinical Trials (DCT): a snapshot



Source: https://pharmaintelligence.informa.com/resources/product-content/2020/07/20/10/43/sitecore/shell/~/media/informa-shopwindow/pharma/2020/covid-24-campaign/slides/decentralized-clinical-trials-in-2020.pdf

Classified as public by the European Medicines Agency



• DCTs are quite a new modality to conduct trials with respect to traditional

research and they are still a little percentage of the volume of studies and trials.

- They are an evolving and important step in the field of clinical research.
- They are particularly useful for patients with rare diseases, for whom the referral center can be very distant and not easily reacheable, for patients with limited mobility and/or functional disability and that are not

autonomous.

My POV

- When dialing with DCTs, technology is a key point.
- Technology must be a facilitator and not a barrier between patient and investigators/health care providers.
- We need strong involvement of patients since the first phases of the planning of the trial project to enhance trust and needings.
- Trasparency for CI disclosure (Investigators) is a key point to reinforce trust and good execution of the studies.



- Digital health technology gives us a continuous and extensive flow of data from patients with respect to traditional on site clinical visits.
- This offers (many) opportunities and threats:
 - More data = more info
 - Continuous flow data = possibilities to intercept earlier signs of alarm
 - Overload for the investigators ?



- Finding a balance between patient needs [e.g. for unscheduled access or visits or meeting (or simply questions)], and healthcare professionals workflow.
- Identifying adequate and secure (certificated?) electronic platforms is needed.
- Adequate training on platforms for investigators and patients is crucial before starting the trial.



Panel discussion to explore patient and investigator site perspective

Panellists:

Sally Hofmeister (World Duchenne Organization) Julián Isla (COMP and Dravet Europe) Aisling Walsh (EFCNI) Mira Zuidgeest (trials@home) Dr Filippo Pieralli (University Hospital Careggi) Dr Francisco Bautista (Princess Máxima)

Moderator:

Kasper Bendix Johnsen (Danish National Center for Ethics)



Closing remarks

Peter Arlett, EMA
Greet Musch, FAMHP/CTCG



End Plenary Session



Appendix

ACRO DCT Working Party Objectives


Scope:

- Landscape scanning to identify and address barriers to adoption of DCTs
- Short-term (6-month) projects to create deliverables to advance DCTs – for use by all stakeholders and available on ACRO website
- Engagement and informal listening sessions with stakeholders to share and discuss ACRO projects (industry, sites, regulators, ethics committees, patients)

How?

- ACRO DCT committee established in 2019
- Committee meets weekly so that all ACRO members can collaboratively develop and complete DCT projects
- Q1 & Q2 each year focuses on project development
- Q3 and Q4 each focuses on project dissemination via informal listening sessions and feedback with stakeholders





Started with...

an in depth analysis of the End-to-end CT Process

The team analysed what is different with a DCT compared to a traditional paper based trial?

ACRO DCT TOOLKIT

Bringing the Trial to the Patient:

A Quality-by-Design Manual for Decentralized Clinical Trials

ACRO Decentralized Clinical Trials Working Party September 2020



Quality by Design DCT Manuals

ACRO

Table of Contents

Executive Summary 1.0 Introduction to Decentralized Clinical Trials 1.1 What is a Decentralized Clinical Trial 2.0 COVID-19 and use of DCT approaches 3.0 na the Trial to the Patient Benefits of Decentralized Clinical Trials. 3.1 3.2 ved patient experience with decentralized clinical trials 3.3 Patient Centricity by Design ... Being connected to decentralized clinical technology. 3.4 Early Engagement with stakeholder 3.5 4.0 ology Quality-by-design Manual. 4.1 End to end process review Quality-by-design Manual for DCTs 4.2 5.0 5.1 5.2 Common Regulatory Requirements. . 13 Data Privacy and Security 5.3 . 13 5.4 idation of Electronic System .. 14 5.5 Electronic Signatures level Aspects of a DCT Design.. 6.1 Data Collection, Handling, and Management Processes and Procedures to end Decentralized Clinical Trial Process . 7.0 End to end Decentralized Clinical Trial Process Graphic 7.1 7.2 eral IT and Systems Considera 7.3 **Trial Planning and Design** 7.4 Early Patient and Stakeholder Engagement 7.5 Itation and Peer Review 7.6 Protocol Development, Protocol Approva 7.7 Trial Monitoring and Managemer 7.8 7.9 Trial Documentation and Trial Master File .. 7.10 30 Contracts and Agrooments 7.11 Feasibility and Site Selection .31 2

ACRO DCT TOOLKIT

ACRO

7.12	2 Ethics Submission	3
7.13	3 Informed Consent	.3
7.14	Inspection & Audit	3
7.15		
	Appendix 1 – Areas not/minimally impacted by a DCT	
8.0	Appendix 1 – Areas not/minimally impacted by a DC1	3.
9.0	Appendix 2 – References	3

July 2021

QbD Manual for Decentralized Clinical Trials: The Quick Reference Guide

ACRO Decentralized Clinical Trials Working Party





Decentralized Clinical Trials (DCT) Risk Assessment Considerations

September 2020

ACRO

Association of Clinical Research Organizations (ACRO)

Decentralized Clinical Trials Working Group

DCT Risk Assessment

- Template to systematically raise questions that facilitate cross-functional discussion to identify and mitigate potential risk in decentralizing trial functions
- Complements a company's existing risk tools
- Leveraging Transcelerate Risk Assessment Categorisation Tool RACT



ACRO DCT TOOLKIT

ACRO

Decentralizing Clinical Trials

A New Quality-by-Design, Risk-Based Framework



DCT White Paper

An ACRO

- White paper to introduce the ACRO Toolkit
- Case studies and experiences running DCTs
- Feedback from authorities






DCT Data Strategy and Data Flow

'Sponsors/CROs need a detailed understanding of the data flow with a data flow diagram that includes: from whom and to whom the data are transferred or transmitted, including all third-party vendors contracted for data collection, data handling, data management and/or data processing'

MHRA/FDA GCP Symposium 2020







Navigating DCT Transformational Change

Attitude and interest towards change? Current levels of support? Concerns and fears? What are seen as key risks? What the barriers that are foreseen? What are the benefits to stakeholders? What happens if we do not change? Points of resistance to change?

[To be published Q4 2022
	Navigating Change during Rapid Transformation: A Question-and-Answer Resource for Decentralized Clinical Trials	
	ACRO Decentralized Clinical Trials (DCT) Working Party October 2022	
	1	



Common DCT Themes with stakeholders



